Ranolazine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Ranolazine
- Ranolazine: From Unconfirmed Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
Ranolazine: From Unconfirmed Original Indication to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
The original approved indication and mechanism of action for Ranolazine are not available in the current dataset. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this prediction is currently supported by no clinical trials and no published literature — it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license/indication data in current dataset) |
| Predicted New Indication | Nephrogenic Syndrome of Inappropriate Antidiuresis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 (model prediction only, no clinical or literature support) |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Ranolazine is not available in this evidence pack, and no original approved indication is on record either. This means the usual basis for assessing biological plausibility — comparing the drug’s known pharmacology against the predicted new indication — cannot be constructed from the data at hand.
The TxGNN score (99.65%, rank 6524) indicates the knowledge-graph model finds a strong statistical association between Ranolazine and NSIAD, but a high model score alone does not establish mechanistic plausibility. Without MOA data and without any supporting clinical trials or literature, the mechanistic link between Ranolazine and NSIAD cannot be independently verified at this time.
Any interpretation of this prediction should be treated as a research hypothesis only, pending retrieval of MOA data and independent evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
No registration records currently found — Ranolazine is not marketed in Taiwan (0 licenses on file).
Safety Considerations
Key warnings and contraindications are not available in the current dataset (blocking data gap — see Conclusion).
Drug Interactions: 233 total interactions on record. Notable Major-level interactions include:
| Interacting Drug | Severity |
|---|---|
| Aprepitant | Major |
| Dexamethasone | Major |
| Clarithromycin | Major |
| Dolasetron | Major |
| Eliglustat | Major |
Moderate-level interactions include Famotidine, Metformin, Loperamide, Bisacodyl, Budesonide (oral and nasal), Canagliflozin, Dapagliflozin, Empagliflozin, and others — largely consistent with a drug metabolized via CYP pathways with sensitivity to strong inhibitors/inducers. Minor-level interactions include Bupropion, Lorcaserin, and Cimetidine.
Conclusion and Next Steps
Decision: Hold
Rationale: Two data gaps block a safety-first evaluation: TFDA label warnings/contraindications are unavailable (Blocking severity, DG001), and MOA data is missing (High severity, DG002). Additionally, the predicted indication (NSIAD) has zero clinical trial or literature support — evidence level is L5, the weakest tier. Combined with the drug’s unmarketed status in Taiwan, there is insufficient basis to proceed.
To proceed, the following is needed:
- Retrieve TFDA (or equivalent regulatory) label warnings and contraindications for Ranolazine
- Obtain MOA data from DrugBank to assess mechanistic plausibility for NSIAD
- Confirm the original approved indication(s) for Ranolazine
- Conduct targeted literature/clinical trial searches for “Ranolazine” + “NSIAD” / “SIADH” / “hyponatremia” to identify any supporting evidence beyond the TxGNN score
- Reassess market status before considering any repurposing pathway in Taiwan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.